XSAU
2070
Market cap918mUSD
Nov 12, Last price
28.88SAR
Name
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1986 and headquartered in Buraydah, Saudi Arabia, Saudi Pharmaceutical Industries and Medical Appliances is dedicated to the development, manufacturing, and marketing of medicinal products and pharmaceutical formulations. Its operational footprint spans the Kingdom of Saudi Arabia, Egypt, the broader Middle East, Morocco, and Algeria. The company's extensive portfolio also includes the production of basic chemical substances, human-use medicines (including cosmetics), and the wholesale and retail distribution of pharmaceuticals and related items. Moreover, it actively develops, produces, and sells medical appliances in addition to pharmaceutical products, and undertakes the operation and maintenance of healthcare facilities. A core aspect of its mission is engaging in advanced research and development within medical science.
Key people
Khalid Bin Abdulrahman Al-G
Non-Executive Chairman of the Board · since 2025
Faisal Al-Fadley
Acting Chief Financial Officer · since 2024
Abdullah Al Rashidi
Chief Operating Officer · since 2024
Mohammed Alassmari
Chief Human Resources Officer · since 2022
Amjad Ali
Chief Internal Auditor · since 2021
Fahad Bin Marzouq Alhonaini Alharbi
Acting Executive Director - Local Private Sales · since 2024
Ahmed Bin Hamdan Al-Jedai
Vice Chairman of the Board, Managing Director · since 2025
Faisal Bin Mohammed Shaker
Non-Executive Director · since 2021
Adel Kareem Kak Ahmed
Non-Executive Director · since 2021
Mohammad Khalil Mohammad
Non-Executive Director · since 2021
Mai Bint Abdullah Al Ajaji
Non-Executive Independent Director · since 2022
Fahad Bin Abdulaziz Al Rab
Non-Executive Independent Director · since 2021
Abdulrahman Bin Mohammed Al Thaniyan
Non-Executive Independent Director · since 2015
Valuation
Title SAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||